Why Would a Newborn Need a Blood Transfusion?

Newborns receive blood transfusions more often than most parents expect, and the reasons range from the predictable consequences of being born early to rare emergencies that develop before or during delivery. Prematurity is by far the most common driver: very small babies have tiny blood volumes, produce red blood cells slowly, and lose a surprising amount of blood to the routine lab tests needed to monitor their care. But immune-related destruction of red cells, bleeding during birth, severe infections, and inherited blood disorders can also push a newborn’s blood counts low enough to require a transfusion within the first days or weeks of life.

Premature Babies and Their Remarkably Small Blood Supply

To understand why transfusions are so frequent in neonatal intensive care units, it helps to appreciate just how little blood a premature infant has. A baby born extremely early may have a total blood volume roughly equivalent to a double espresso, around 80 milliliters or so depending on birth weight.¹ A full-term baby has more, but even then the total is only a few hundred milliliters. That means every blood draw for lab work removes a proportionally large share of the baby’s circulating red cells.

In the first weeks of life, premature infants typically need frequent monitoring of blood gases, electrolytes, blood counts, and infection markers. Each sample is small by adult standards, but the cumulative loss adds up fast in a baby weighing one or two pounds. Research has consistently identified laboratory phlebotomy loss as a main cause of anemia leading to red blood cell transfusion during the first ten weeks of life in extremely low birth weight infants.² Neonatal units have worked to reduce sample sizes and use point-of-care devices that need smaller volumes, but the problem has not been eliminated.

Anemia of Prematurity

Beyond phlebotomy losses, premature infants face a biological disadvantage in replacing the red blood cells they lose. Every baby’s red cell production drops after birth as the body adjusts from the low-oxygen womb environment to breathing air, but in preterm infants this dip is steeper and lasts longer. A key reason is that their bodies rely on the liver rather than the kidneys to produce erythropoietin, the hormone that signals the bone marrow to make new red blood cells. The liver is less efficient at this job, so erythropoietin levels stay too low to keep up with the demand.³ The switchover to kidney-based production happens gradually and is incomplete in babies born weeks ahead of schedule.

Add phlebotomy losses on top of that sluggish red cell production, and it becomes clear why so many premature infants end up needing one or more transfusions. Sicker babies who require intensive monitoring tend to need more draws, creating a cycle where the very act of keeping a close eye on the baby’s health contributes to the anemia being treated.⁴

Blood Group Incompatibility and Immune-Driven Destruction

Sometimes a newborn’s red blood cells are being actively destroyed by the baby’s own immune system, or more precisely, by antibodies passed from the mother during pregnancy. This is the category doctors call hemolytic disease of the fetus and newborn, and it happens when the mother’s blood type is incompatible with the baby’s in a way that triggers an immune response.

Rh disease is the most historically dramatic form. When an Rh-negative mother carries an Rh-positive baby, fetal red cells that leak into her bloodstream can trigger the production of antibodies. During a first pregnancy, the antibodies produced are typically too large to cross the placenta and do not harm the baby. But in a subsequent pregnancy with another Rh-positive fetus, the mother’s immune system produces smaller antibodies that do cross, attaching to fetal red cells and marking them for destruction.⁵ Before preventive treatment became available in the 1960s, Rh disease was a major cause of severe illness and death among newborns.⁶ The widespread use of anti-D immunoglobulin injections given to Rh-negative mothers during and after pregnancy has slashed rates dramatically, though the condition has not disappeared entirely.

ABO incompatibility is actually more common but usually milder. It typically arises when the mother has type O blood and the baby has type A or B. In one study of neonatal hyperbilirubinemia, ABO incompatibility accounted for about 29% of cases with blood group mismatch, while Rh incompatibility accounted for roughly 5%.⁷ In either type of incompatibility, the destruction of red cells floods the baby’s system with bilirubin, a waste product that causes jaundice. When bilirubin levels climb dangerously high, a special procedure called an exchange transfusion may be needed. This involves slowly removing the baby’s blood in small increments and replacing it with donor blood, which washes out both the harmful antibodies and the excess bilirubin. In one large retrospective series, Rh and ABO incompatibility together accounted for about three-quarters of all exchange transfusions performed over a 17-year period.⁸

Bleeding Before or During Birth

Some newborns arrive already anemic because of blood loss that occurred in the womb or during delivery. One scenario is fetomaternal hemorrhage, where a significant volume of fetal blood crosses the placenta into the mother’s circulation. Small leaks happen in most pregnancies and cause no harm, but a large hemorrhage close to delivery can leave the baby in shock, with dangerously low blood pressure and metabolic imbalances that require immediate transfusion.⁹

In identical twins who share a placenta, an unequal distribution of blood flow between the two fetuses can develop. Twin-to-twin transfusion syndrome occurs in roughly 10 to 15% of these pregnancies, as blood is shunted from one twin (the “donor”) to the other (the “recipient”) through shared blood vessel connections on the placenta’s surface.¹⁰ The donor twin can become severely anemic, while the recipient twin becomes overloaded with blood. Both may need treatment after birth, and in severe cases, the donor twin may require urgent transfusion. In one reported case, the anemic donor twin developed brain injury and died at six days of life despite delivery at 34 weeks.¹¹ Placental abruption, cord accidents, and traumatic deliveries are other routes through which a newborn can lose enough blood to need a transfusion immediately.

Infections and Inherited Blood Disorders

Severe infections in newborns can trigger anemia through several pathways. Sepsis may suppress the bone marrow’s ability to produce red cells, increase the rate at which red cells are destroyed, or cause a dangerous clotting disorder called disseminated intravascular coagulation that consumes blood components. In the most critical cases, exchange transfusion has been used as a last-resort treatment to clear toxins and replace depleted blood components.¹²

Some babies are born with inherited conditions that make their red blood cells fragile or short-lived. The most common congenital hemolytic anemias seen in newborns include G6PD deficiency, pyruvate kinase deficiency, and hereditary spherocytosis.¹³ G6PD deficiency is especially widespread globally and can cause sudden, severe destruction of red cells when triggered by certain medications, infections, or foods. In hereditary spherocytosis, red blood cells are misshapen and get trapped and destroyed in the spleen at an accelerated rate. Babies with these conditions may present with unexplained jaundice or anemia shortly after birth and can need transfusions to tide them over until they are stable enough for longer-term management.

Not Just Red Cells

When people hear “blood transfusion,” they usually picture a bag of red blood cells, and that is indeed the most common type given to newborns. But neonatal intensive care units also use other blood products. Platelets are given to babies with very low platelet counts, which can occur in severe infections or certain immune conditions and raises the risk of dangerous bleeding. Fresh frozen plasma, which contains clotting factors, is used when a baby has an abnormal clotting profile. One study of transfusion practices in a neonatal ICU found that while platelet and plasma transfusions did improve laboratory numbers, the clinical benefit in terms of stopping or preventing active bleeding was less clear.¹⁴ This is an area where practice is still evolving, and doctors weigh the risks of transfusion against the risk of hemorrhage in a baby whose clotting is impaired.

How Doctors Decide When to Transfuse

There is no single hemoglobin number that automatically triggers a transfusion in every newborn. The threshold depends on how old the baby is, how premature they were, whether they need breathing support, and how well they are tolerating their anemia. A baby on a ventilator with high oxygen demands will typically be transfused at a higher hemoglobin level than a stable baby who is breathing on their own and gaining weight.

A long-running debate in neonatal medicine has been whether to transfuse at higher (“liberal”) or lower (“restrictive”) hemoglobin thresholds. A large trial published in the New England Journal of Medicine randomly assigned extremely preterm infants to one strategy or the other and found that rates of death and neurodevelopmental impairment at two years were virtually identical between the groups.¹⁵ A meta-analysis of twelve randomized trials confirmed that both strategies appear broadly safe, though the liberal approach may shorten the time babies spend on supplemental oxygen and breathing support.¹⁶ An earlier trial had hinted that restrictive thresholds might be linked to slightly worse cognitive outcomes, but the finding was not statistically significant and only emerged in a post-hoc analysis.¹⁷ In practice, most neonatal units now use threshold guidelines that vary by the baby’s age and clinical status, aiming to transfuse when needed without over-transfusing.

Risks That Come With Neonatal Transfusions

Blood transfusions are not risk-free, and in the neonatal population some of the risks take on added weight. One concern specific to premature infants is a possible link between transfusion and necrotizing enterocolitis, a devastating bowel disease. Necrotizing enterocolitis that arises within 48 hours of a transfusion has been observed in roughly a quarter to a third of NEC cases in some studies, and the affected infants tend to be smaller, more premature, and more severely ill.¹⁸ Whether the transfusion itself contributes to the bowel injury or whether sicker babies simply receive more transfusions and are already at higher risk remains debated.

Newborns also have immature immune systems, making them vulnerable to infections transmitted through blood products. Cytomegalovirus is a particular worry for very low birth weight infants. To reduce these risks, blood products used in neonatal units are typically both leukoreduced (white blood cells are filtered out) and irradiated (to prevent donor immune cells from attacking the baby’s tissues).¹⁹ Modern blood banking also screens for CMV status, and units intended for high-risk newborns are selected from CMV-negative donors or undergo additional testing.²⁰

Do Transfusions Affect Long-Term Development?

This is one of the most unsettling questions for parents. Several studies have found that the number of transfusions a premature baby receives is statistically associated with lower cognitive and motor scores at age two. In the PENUT trial, each additional transfusion was linked to roughly a one-point drop in cognitive scores and about a one-and-a-half-point drop in motor scores on standardized developmental testing.²¹ Another study found a similar pattern, with each transfusion independently associated with a small reduction in general developmental scores at 24 months, and the effect persisting to age five in babies without brain lesions.²²

The critical nuance here is that these are observational associations, not proof that the transfusion itself caused the developmental differences. Babies who need more transfusions are, almost by definition, sicker, smaller, or more premature. After adjusting for gestational age, baseline illness severity, and socioeconomic factors, the association between transfusion number and decreased cognitive and motor function has persisted in some analyses but has not been confirmed as causal.²³ The large randomized trial comparing liberal versus restrictive thresholds found no meaningful difference in developmental outcomes at two years, which argues against the transfusions themselves being a major culprit.¹⁵ In other words, a baby who genuinely needs a transfusion should get one; the developmental associations likely reflect the underlying severity of the baby’s condition rather than harm from the blood itself.

Strategies That Reduce the Need for Transfusion

One of the simplest and most effective interventions happens in the delivery room: waiting 30 to 60 seconds before clamping the umbilical cord. This short delay allows blood from the placenta to flow into the baby, boosting blood volume and red cell counts. In preterm infants, delayed cord clamping has been linked to lower mortality and a reduced need for transfusion.²⁴ One study of very low birth weight infants found that those who received delayed clamping were about 55% less likely to need a red blood cell transfusion compared with those whose cords were clamped immediately.²⁵

Other strategies used in neonatal units include minimizing blood draw volumes by using micro-sampling techniques, grouping lab tests to reduce the number of separate draws, and monitoring with noninvasive technology when possible. Erythropoietin, the red-cell-boosting hormone that premature babies underproduce, has been tested as a medication to stimulate blood cell production and reduce transfusion needs. It has shown some success in cutting the number of transfusions, and interestingly, the PENUT trial observed that the negative association between transfusion count and developmental scores was present in the placebo group but not in the group receiving erythropoietin.²¹ Whether that protective signal holds up in further study remains to be seen.

Experimental Frontiers

Looking further ahead, researchers have begun exploring synthetic blood products for neonatal use. In one experimental program, extremely premature sheep fetuses were maintained on an artificial placenta system using a preparation of synthetic red cells to carry oxygen. The animals survived up to 72 hours on the platform, and while the researchers acknowledged that significant refinements are still needed, the results demonstrated the potential for synthetic blood to eventually support extremely premature infants in clinical settings.²⁶ These technologies remain firmly in the animal-testing stage, but they hint at a future where the smallest and most fragile patients might be supported without relying entirely on human donor blood.